Global Pulmonary Drugs Market Study 2016-2026, by Segment (Inhaled Corticosteroids (ICS), Long-Acting Beta2-Agonists (LABA), … …), by Market (Asthma & COPD, Allergic Rhinitis, … …), by Company (AstraZeneca plc, Bayer AG, … …)

SKU ID :99ST-14631990 | Published Date: 29-Oct-2019 | No. of pages: 59
Summary

The global Pulmonary Drugs market will reach Volume Million USD in 2019 and with a CAGR xx% between 2020-2026.

Product Type Coverage (Market Size & Forecast, Major Company of Product Type etc.):


Inhaled Corticosteroids (ICS)
Long-Acting Beta2-Agonists (LABA)
Antihistamine
Vasodilators
Short-Acting Beta2-Agonists (SABA)
Anticholinergics
Combination Drugs
MAbs
Enzymes
Antibiotics & Antileukotrienes
Demand Coverage (Market Size & Forecast, Consumer Distribution):
Asthma & COPD
Allergic Rhinitis
Pulmonary Arterial Hypertension
Cystic Fibrosis

Company Coverage (Sales data, Main Products & Services etc.):


AstraZeneca plc
Bayer AG
Teva Pharmaceutical Industries Ltd
Actelion Pharmaceuticals, Inc.
Boehringer Ingelheim GmbH
F. Hoffmann-La Roche Ltd.
Merck & Co., Inc.
Novartis AG
GlaxoSmithKline plc
Sunovion Pharmaceuticals

Major Region

Market
North America
Europe
Asia-Pacific
South America
Middle East & Africa
  • PRICE
  • $1800
    $3600
    Buy Now

Our Clients